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Signal transduction of erythropoietin in endothelial cells. Erythropoi-
etin (EPO) induces endothelin expression in endothelial cells (EC) and
has angiogenic effects. We investigated the intracellular signal transduc-
tion of EPO in EC and tested the hypothesis that the proliferative effects
of EPO may be mediated by cytosolic calcium, changes in intracellular pH,
or tyrosine phosphorylation. Cytosolic calcium and pH were measured
with fura-2 and BCECF. Protein phosphorylation was assessed with
32P-labeled EC and two-dimensional (2D) gel chromatography. Tyrosine
phosphorylation was measured using specific antityrosine antibodies and
confocal microscopy. Proliferation was measured by thymidine incorpo-
ration and cell count. No effects of EPO on cytosolic calcium and pH were
observed. In contrast, erythropoietin increased phosphorylation of 94, 70,
42,40, 29 and 25 kDa proteins at five minutes and 60 minutes. Most of the
early proteins were tyrosine phosphorylated. Confocal microscopy showed
cytosolic as well as membrane-bound tyrosine phosphorylation in resting
cells and an EPO-induced translocation of immunoreactivity to the
nucleus. Immunostaining for the transcription factor STAT-5 showed that
EPO induced a nuclear transfocation of STAT-5. EPO 0.5, 2, and 4 U/ml
increased proliferation, an effect that was prevented by incubation with the
tyrosine kinase inhibitor genistein. We conclude that EPO induces prolif-
eration in EC initially via tyrosine phosphorylation of six distinct proteins,
and that the phosphorylation and nuclear translocation of the transcrip-
tion factor STAT-S is important for the effects of EPO on EC.
The treatment with recombinant human erythropoietin (EPO)
for the treatment of anemia in end-stage renal disease patients is
associated with hypertension and thrombo-embolic complications
[1—51. The cause of EPO-associated hypertension is not yet clear;
however, several authors have suggested a direct EPO-induced
effect on the vascular wall [2, 5, 6]. Recently, Anagnostou et a! [7]
described the occurrence of specific EPO receptors on endothelial
cells (EC). This finding suggests that EPO may exert its effects on
the vascular wall via a direct stimulation of EC. In agreement with
this hypothesis, others have shown that EPO induces protein
expression and secretion of endothelin-1 in EC [3, 8]. Moreover,
EPO has a proliferative effect on EC and is capable of inducing
angiogenesis [7, 9],
The intracellular signal transduction of the EPO receptor has
been investigated mainly in erythroid progenitor cells. After EPO
binding to its receptor, rapid tyrosine phosphorylation of numer-
ous cellular proteins occurs, including the receptor itself [10—12].
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EPO also appears to exert its proliferative effects in these cells via
the Janus (JAK) kinases. Activation of the JAK kinases leads to
tyrosine phosphorylation of signal transducers and activators of
transcription, so-called STAT proteins. The STAT proteins are
present in the cytosol of resting cells and are translocated to the
nucleus after EPO receptor binding [131. Since both endothelial
and erythroid progenitor cells descend from angioblasts of mes-
enchymal origin, it is possible that EPO's signal transduction
pathway in EC is similar to the mechanisms described in erythroid
progenitor cells. However, the signal transduction of EPO in EC
has not been investigated.
Our specific aim was to elucidate the signal transduction of
EPO in EC. Since EPO reportedly causes EC to proliferate, we
specifically wanted to know which mitogenic signals are responsi-
ble. In addition to the tyrosine kinase pathways, mitogenic
signaling by growth factors can also be mediated by changes in
intracellular free calcium concentration ([Ca2]) or alkalization
of the cytosol [14, 151. In fact, EPO reportedly induces a dose-
dependent increase in [Ca2] in human erythroblasts [16]. Fur-
thermore, EPO increasese [Ca2]1 in platelets and vascular
smooth muscle cells [6, 17]. We therefore investigated the effects
of EPO on [Ca2], pH, and tyrosine phosphorylation in EC. In
addition, we analyzed the EPO-mediated effects on EC growth.
We could not find an effect on either [Ca2]1 or pH. Instead, we
demonstrated that EPO induces tyrosine phosphorylation of 6
phosphoproteins and showed that nuclear translocation of
STAT-S plays a role in EPO-induced signal transduction in EC.
Methods
Materials
All materials, if not stated otherwise, were purchased from
Sigma (Deisenhofen, Germany). EPO was recombinant erythro-
poietin and was a gift from Cilag Pharmaceuticals (Bad Nauheim,
Germany). Antibodies for tyrosine phosphorylated residues used
in Western blot analysis were monoclonal (mouse) and obtained
from Oncogene Science (New York, NY, USA). Antibodies for
tyrosine phosphorylated residues used in immunohistochemistry
were FITC-labeled monoclonals and obtained from Transduction
Laboratories (Hamburg, Germany). 32P was obtained from Am-
ersham (Arlington Heights, IL, USA). The fluorescent probes
fura-2-AM and BCECF were purchased from Serva (Heidelberg,
Germany). Antibodies for STAT-i, STAT-2 and STAT-5 were
from Dianova (Hamburg, Germany). Genistein was obtained
from Gibco Life Technologies (Gaithersburg, MD, USA).
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Culture procedures
Human umbilical vein EC were isolated from umbilical cords by
chymotrypsin treatment as described previously [18]. The cords
were cleaned with isotonic NaCl buffer at room temperature and
incubated for 25 minutes at 37°C with 1% chymotrypsin in PBS
(Seromed, Berlin, Germany). EC were then removed by centrif-
ugation (400 g for 10 mm), the pellet resuspended in M-199
(Seromed) with 20% fetal calf serum, 1% L-glutamine, 1%
non-essential amino acids (Seromed), 1% HEPES (Gibco), 1%
Na-pyruvate, 1% Schutzmedium (Seromed), as well as streptomy-
cm and penicillin. Primarily cultured cells were grown for three to
four days and then subcultured. Subcultures 1 to 3 were used for
the experiments.
Phosphoiylation studies
The culture medium was removed and cells were incubated with
30 ml minimum essential medium without phosphate (minimum
essential Eagle medium with Earl's salts, sodium bicarbonate and
L-glutamine without sodium phosphate, Sigma Chemical Co. (St.
Louis, MO, USA) and phosphorus-32 (32P as orthophoshoric acid
in aqueous solution without HCI, 300 >< 10—6 Ci) for six hours
[19]. Afterwards, the radioactive medium was removed and MEM
without phosphate was re-added. After EPO exposure for the
described times, the cells were removed with a cell scraper and
suspensions were centrifuged for seven minutes at 500 g. The
pellets were then transferred to 2 ml Eppendorf tubes and
centrifuged for another five minutes at 500 g. The pellets were
frozen in liquid nitrogen, homogenization buffer [Tris 50 M, NaCl
0.1 M, DTT 5 mivi, PMSF 1%, Leupeptin 125 mi (Boehringer
GrnbH, Mannheim, Germany), 1% 10_s M okadeic acid, 0,1%
50- M vanadate] were added and cells homogenized ultrason-
ically. Lysates were centrifuged at 3000 g and the supernatant
dissolved in sample buffer (urea 60%, 2% Nonidet P-40, 1%
dithiothreitol). The samples were then loaded onto gels and
two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)
was performed using the PhastSystem (Pharmacia LKB Biotech-
nology, Uppsala, Sweden).
Both dimensions were run horizontally. For isoelectric focusing,
gels (CleanGel IEF for PhastSystem; Pharmacia Biotechnology)
were rehydrated in a solution of urea (48%), Nonidet P-40
(0.25%), and ampholyte (0.75%) (2/3 Pharmalyte 2.5-5, 1/3 Phar-
malyte 3-10, Pharmacia). After isoelectric focusing, I to 3 mm
strips were cut from the gel and equilibrated in SDS-containing
buffer (0.112 M Tris, 0.112 M HAc, 1% DTT, 2.5% SDS, 0.1%
bromphenol blue). The strips were then placed directly upon the
stacking gel zone of the gradient gel with 8 to 25% polyacrylamide
(PhastGel gradient 8 to 25, Pharmacia). After electrophoresis
(SDS-PAGE), gels were blotted also using the PhastSystem
(Pharmacia) onto membranes (Millipore Corporation, Bedford,
MA, USA).
Tyrosine phosphorylation was also determined by Western
blotting. The concentration of EPO used was 20 U/ml. The first
incubation was conducted in antibody diluted in incubation buffer
containing 137 mrvt NaC1, 20 mrvi Tris-HCI pH 7.5 and 1% BSA at
room temperature. A final incubation was carried out in TBS with
alkaline phosphatase conjugated anti-rabbit or anti-mouse IgG
(Oncogene Science, NY, USA). The membranes were thoroughly
washed after each incubation with a buffer containing 137 mM
NaCI, 20 mist Tris-HCI pH 7.5, and 0.2% (vol/vol) Tween-20.
Quantification of the phosphorylated areas on the blots was done
by densitometry on a Biorad video densitometer 620. The signals
were then integrated and the results were expressed in arbitrary
units.
Flow cytometly
Endothelial cell proliferation was measured by flow cytometry
[18]. Endothelial cell cultures were stimulated with EPO as
indicated, washed, and removed from tissue culture by treatment
with 0.02% ethylene diamine-tetra-acetic acid (EDTA) or trypsin.
Cells were then centrifuged for 10 minutes at 400 g, diluted in 2 ml
of PBD with 1% paraformaldehyde and were counted on an
automated fluorescence associated cell separation system (FAC-
Scan; Becton Dickinson Immunocytometry Systems, San Jose,
CA, USA).
Immunocytochemistiy
The techniques we use for confocal microscopy are described in
detail elsewhere [20-22]. The cells were fixed with 3% parafor-
maldehyde and permeabilized with 80% methanol at —20°C.
After incubation with 3% skimmed milk in phosphate buffer
solution (SM/PBS) for 60 minutes, the preparation was incubated
for one hour at room temperature with the anti-tyrosine diluted in
PBS with 0.1% BSA (1:80) and washed thrice with PBS. The
preparation was mounted with 50% glycerol under a glass cover-
slip on a Nikon-Diaphot (Tokyo, Japan) microscope. A Biorad
MRC 600 confocal imaging system (Bio-Rad Laboratories,
Freiburg, Germany) with an argon-krypton laser (488 nm wave-
length) was used. Subcellular localization of phosphorylated ty-
rosine was carried out with a pinhole setting of the confocal
aperture resulting in a z-resolution of approximately 0.5 mm. At
least 20 cells from each of at least seven experiments were
examined under each experimental condition. The reproducibility
of the results was verified by two separate investigators and
multiple experiments were done. The observers were unaware of
the experimental design and the antibodies used. Quantification
of the signal intensity was done with histogram/area functions in
the MRC - Comos software. The cells were outlined manually and
the calculated mean fluorescent intensity was obtained.
[Ca2J and pH in single cells
For [Ca2] and pH, cells were sowed on coverslips and
incubated at 37°C for one to two days [22, 23]. The calcium
measurements were performed using a Spex DM 3000 CM
spectrofluorometer, which was connected to a Nikon epifluores-
cence microscope (Tokyo, Japan) and a variable-aperture pho-
tometer for isolating individual cells on the microscope stage
(Spex Industries Inc., Edison, NJ, USA). Cultured EC were
loaded with fura-2 with a 20-minute incubation in PBS containing
5 /LM fura-2-AM (added from a 5 m stock solution in DMSO).
Fluorescence of calcium-bound and unbound fura-2 was deter-
mined by rapidly alternating (0.1 second) the exciting radiation
between 340 and 380 nm and separating the resulting emission
signals at 505 nm electronically. The maximal fluorescence ratio
(Rm) was determined by adding 40 j.tM ionomycin (using a 0.01
M stock solution in DMSO). The minimal fluorescence (Rmj) was
obtained by adding 0.25 M EGTA at pH 7.8. The ratio of the two
signals was used to calculate [Ca2] as described elsewhere [23].
All experiments were carried Out at room temperature. For
intracellular pH, cells were loaded with BCECF-AM in PBS
containing 5 jIM BCECF-AM (added from a 5 m stock solution
in DMSO) during a 20-minute incubation. BCECF fluorescence
was assessed at room temperature by measuring emission signals
at 498 nm.
Statistics
The non-parametric Wilcoxon test and a one-way ANOVA
were used. Differences were considered to be significant when P
was  0.05. The terms increase and decrease were applied only
when the results were significant.
Results
Figure 1 shows the effect of EPO (20 U/mI) on intracellular pH
(N = 24) (Fig IA) and [Ca2]1 (N = 8; Fig IB) in single
endothelial cells. EPO showed no effect on intracellular pH or
[Ca2j. EPO in lower concentrations (0.02, 0.05, 0.1, 0.2, and 1.0
U/ml) also had no effect on [Ca2j1. In contrast, thrombin (0.1
U/mi) induced a rapid increase in [Ca211. We next investigated
the effects of EPO on protein phosphorylation in cultured EC.
Figure 2A shows the two-dimensional gel electrophoresis of EC
exposed to EPO (10 U/mi) at rest, and after 5 and 60 minutes. In
Figure 2B the densitometric semiquantitation of the phosphory-
lation data are shown (N = 4). Five minutes of exposure to EPO
led to an increased phosphorylation of distinctly six proteins. The
highest increase in protein phosphorylation showed a 70 kDa and
a 40 kDa protein. Two phosphoproteins with a kDa of 29 and 25
were not visible in resting cells, but appeared after five minutes of
EPO. These two proteins are marked by arrows on the blot.
We then asked the question of whether or not EPO induces
tyrosine phosphorylation as shown in Figure 3. The cell homoge-
nates underwent gel electrophoresis and were stained with anti-
tyrosine antibodies. A prominent effect was visible at five minutes
and generally increased more gradually thereafter. A marked
increase in tyrosine phosphorylation was observed in proteins with
a molecular weight around 94 kDa. Further analysis of these
proteins is shown in the two-dimensional gel electrophoresis of
the tyrosine phosphorylation pattern in EPO-treated EC as shown
in Figure 4. A tyrosine phosphorylated 94 kDa protein is clearly
visible. In addition, proteins with molecular weights of 28 and 25
kDa, as well as proteins between 40 and 42 kDa, are recognizable.
The molecular weight and the migration pattern of these tyrosine
phosphorylated proteins are similar to the six proteins described
in the experiments using 32P labeled EC. Furthermore, additional
tyrosine-phosphorylated proteins with molecular weights around
36 to 38 kDa were demonstrable.
We next used confocal microscopy to analyze the intracellular
distribution of the tyrosine phosphorylated proteins. A represen-
tative photomicrograph of these experiments is shown in Figure 5.
Fluorescence intensities are displayed in pseudocolors, where
blue indicates a low fluorescence intensity while green, yellow and
red indicate the increasing fluorescence intensities. In resting cells
only very little immunoreactivity for tyrosine residues was ob-
served. No immunoreactivity was present in the nuclear area.
After exposure of the cells to EPO (20 U/mI), a dramatic increase
in intracellular immunoreactivity tyrosine phosphorylated resi-
dues was observed. Tyrosine phosphorylation was present in focal
areas near the plasma membrane. The highest fluorescence
intensity was observed in the nuclear area. At 60 minutes, tyrosine
phosphorylation was greatly reduced and mostly present in dis-
tinct spot in the perinuclear area.
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Fig. 1. Effect of EPO (20 U/mi) on intracellular
pH (A) and [Ca2 (B). EPO had no effect on
either or pH [Ca21. In contrast, thrombin (1
U/mI) induced a rapid increase in [Ca21.
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Fig. 2. Two dimensional gel electrophoresis (A)
showing the effect of FF0 on protein
phosphotylarion in EC. Cells were grown in
EGM on gelatin-coated plastic dishes and
labeled with 32p, exposed to EPO (20 U/mI) Cc,
5 and 60 minutes and homogenized. EPO
induced phosphorylation of 6 distinct proteins.
Semiquantitative densitometric analysis (B) of
the EPO-induced effects on protein
phosphorylation at 0 , 5 (U) and 60 (•)
minutes. A prominent effect was visible aheady
at five minutes and generally increased more
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Fig. 3. Effect of EPO on tyrosine phosphotylation. The cell homogenates
then underwent gel electrophoresis and were stained with anti-tyrosine
antibodies. At five minutes a prominent phosphoiylation was observed.
One of the tyrosine phosphorylated substrates of EPO in
non-endothelial cells is the transcription factor STAT-5. This
protein has a molecular weight of 92 kDa, is rapidly tyrosine
phosphorylated, and is translocated into the nucleus upon expo-
sure of cells to EPO. Using confocal microscopy, we therefore
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investigated the hypothesis that the 92 kDa protein that is
tyrosine-phosphorylated by EPO (see above) is translocated into
the nucleus by EPO. In Figure 6, a representative photomicro-
graph of these experiments is shown. In resting cells, immunore-
activity of STAT-5 was scarce and mostly localized in focal spots
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Fig. 4. Two dimensional gel electrophoresis showing the effect of EPO on
tyrosine phosphoiylation at five minutes. Distinct spots were visible at five
minutes similar to those described in Figure 3.
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Fig. 5. Effect of EPO (20 U/mi) on intracellular distribution oftyrosinephosphoiylation using confocal microscopy of EC stained with antityrosine antibodies.
Fig. 6. Effect of EPO (20 U/mI) on intracellular distribution of STA T-5 using conf cal microsc py of EC stained with antibodies for STAT-5.
in the cytosol. Exposure of the cells to EPO induced a rapid
increase of immunoreactivity for STAT-5 in the cytosol. The
highest fluorescence intensity was observed in the nucleus, indi-
cating translocation of STAT-i immunoreactivity to the nucleus at
five minutes. The increase in nuclear immunoreactivity decreased
thereafter and was barely visible after 60 minutes. When antibod-
ies against STAT-i and STAT-2 were used in these experiments,
we did not observe a significant immunoreactivity in EC and no
effect of EPO was present.
We then tested whether the inhibition of tyrosine phosphory-
lation was associated with a decrease in EPO induced cell growth.
We had shown in preliminary experiments that exposure to the
tyrosine kinase inhibitor genistein (10 M) abolished the EPO-
induced tyrosine phosphorylation (not shown). Figure 7 shows the
effects of EPO on cell number. Basic fibroblast growth factor
(bFGF) was the positive control. EPO induced a small prolifera-
tive effect at 0.5 UIml. Higher doses led to a further increase. The
effect at 4 U/ml was about half that of bFGF. Furthermore, EPO
enhanced the proliferative effect of bFGF significantly (N = 5,
P < 0.05). When cells were exposed to EPO (2 U/mI, N =6) and
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Fig. 7. Effects of EPO and bFGF on the
proliferation of cultured human endothelial cells
(EC). Cells were grown in EGM on plastic,
gelatin-coated culture dishes and exposed to
EPO (4 U/mI) or bFGF (4 X 10 M) for five
days. The effects of EPO and bFGF were
inhibited with the concomitant administration
of the tyrosine kinase inhibitor genistein (1 ><
i0 M). *p < 0.05 compared to control.
genistein (10 M) together, the proliferative effect was abolished
(P < 0.05).
Discussion
We found that EPO induced tyrosine phosphorylation of six
distinct proteins in EC, one of which is the transcription factor
STAT-S. We demonstrated that the enhanced growth of EC was
blocked by inhibitors of tyrosine phosphorylation, indicating that
tyrosine phosphorylation is the intracellular signal that is respon-
sible for the EPO-induced EC growth. In contrast, we could not
observe any effect of erythropoietin on [Ca2]1 or pH.
Several authors have described similar EPO-mediated effects in
erythroid and lymphoid cells [11, 24—27]. The EPO receptor
belongs to a novel class termed the hematopoietic receptor super
family, which shares a common cytokine binding domain [25, 28].
The EPO receptor has no intrinsic tyrosine kinase activity [25, 28].
Activated EPO receptors devoid of intrinsic tyrosine kinase
activity interact via their SH3-domain with tyrosine kinase, either
directly or through a coupling protein. Thus, the intracellular
phosphatidyl inositol-3-kinase and the JAK kinases bind to acti-
vated EPO receptors [26, 29—351. The binding of these intracel-
lular tyrosine kinases then leads to phosphorylation of distinct
substrates. Our data suggest that these mechanisms are also
present in human EC.
We observed six tyrosine phosphorylated proteins of molecular
weights 92 kDa, 70 kDa, 42 kDa, 40 kDa, 29 kDa, and 25 kDa,
after the exposure of EC to EPO. Several recent reports in other
cell types have shown a partially different phosphotylation pattern
[12, 36—401. Dusanter-Fourt et al observed in the hematopoietic
cell line UT-7 the tyrosine phosphorylation of six proteins with
molecular weights of 140 kDa, 120 kDa, 95 kDa, 75 kDa, 60 kDa,
57 kDa, 42 kDa [12]. Yoshimura and Lodish described a tyrosine
phosphorylated 130 kDa protein [371, which was associated with
the EPO receptor. Odai et al described a 130 kDa protein that
becomes tyrosine phosphorylated rapidly and transiently depend-
ing on EPO stimulation, which they identified as the protoonco-
gene c-Cbl [411. They suggested that c-Cbl is implicated in
EPO-induced signal transduction in hematopoietic cells. We did
not observe tyrosine phosphorylated proteins of this molecular
weight, which may indicate that the c-Cbl pathway is not present
in EC.
Some of the phosphoproteins that were demonstrated in hema-
topoetic cells had molecular weights similar to those we observed
in EC. The 42 kDa phosphoprotein in our study and in other
investigations could be the mitogen-associated protein (MAP)
kinase. Miura et al showed that EPO induces phosphoiylation of
MAP kinase and suggested activation of MAP kinases through the
Ras signaling pathway which may be activated by tyrosine phos-
phorylation of She and its association with Grb2 [42]. Several
authors showed that EPO induces tyrosine phosphorylation of its
own receptor [10, 12, 37]. This effect probably involves cross-
linking of two EPO receptors and then phosphorylation of the
bound receptors by receptor-associated cytosolic tyrosine kinases.
Anagnostou et al described this phenomenon in EC [43]. In their
study, the low affinity receptor for EPO on EC had a molecular
weight of 42 kDa. This finding would be compatible with our
observation that a 40 kDa protein was tyrosine phosphorylated.
However, in contrast to the study by Anagnostou et al, the 40 kDa
protein showed a certain amount of tyrosine phosphorylation,
even in the non-stimulated cells. We can only speculate that the
observed phosphoproteins in our study relate to these substrates.
This possibility will require further investigation.
Our experiments suggest that the 92 kDa phosphoprotein that
was rapidly induced by EPO is STAT-5, a member of the signal
transducers and activators of transcription from the so-called
STAT protein family. A phosphoprotein of similar molecular
weight has been reported in human [121 and in murine hemato-
poietic cells [44, 45]. STAT proteins play an important role in
cytokine signal transduction in conjunction with JAK kinases. As
shown earlier, EPO stimulates STAT-S and induces tyrosine
phosphorylation of STAT-S [46]. In resting cells, STAT-5, like the
other STATs, is located in the cytosol. We were able to show that
cytosolic STAT-5 is rapidly translocated to the nucleus by EPO.
This nuclear translocation of STAT-S after tyrosine phosphoryla-
tion has also been observed in other cell types [13, 47—49].
However, we are the first to demonstrate that this mechanism is
also present in EC and that STAT-S plays a part in EPO signaling.
We did not observe any EPO effects on [Ca]. This finding is
in contrast to the observations of other investigators [6, 16, 17].
Miller et al demonstrated that EPO stimulates [Ca2I entry and
suggested that tyrosine kinase activation is required for the rise in
[Ca2] [16]. Weinreich et al and Tepel et al showed an increase
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in [Ca2] in vascular smooth muscle cells in culture after expo-
sure to EPO. From these findings, they concluded that EPO had
a direct contractile effect on mesangial cells and vascular smooth
muscle cells. However, their results could not be confirmed by
others [501.
We believe that our findings could be of physiological signifi-
cance. The proliferative effect was observed using high, supra-
physiological EPO concentrations. However, similar concentra-
tions are achieved in man shortly after intravenous EPO infusions,
or under severe hypoxic conditions. Interestingly, Carlini et al [3]
observed an EPO effect on blood pressure only in those hemodi-
alysis patients receiving intravenous EPO and not in patients
receiving the drug subcutaneously. One might speculate that only
the high concentrations reached by EPO during intravenous
application lead to direct effects of EPO on EC. Recently, several
investigators described an increased expression and enhanced
release of endothelin-1 from EC by EPO [1, 3, 81. These authors
also used very high concentrations. EPO may act as a co-
stimulator of EC. As Carlini et a! [3] have shown, EPO further
enhances the effects of angiotensin II and other factors on the
release of endothelin-1 from EC. EPO, together with other
proliferative agents such as bFGF and PDGF, may enhance the
activation of EC and may contribute to EC proliferation under
hypoxemic conditions. Anagnostou et al found that the EPO
receptor on EC is a low affinity receptor and is distinct from the
receptor observed on hematopoietic cells. This finding supports
our line of argument [7, 31.
In summary, we found that EPO induces growth and tyrosine
phosphorylation in human EC. The proliferative effect was
blocked by genistein, indicating that tyrosine phosphorylation was
responsible for EPO's proliferative activity. No effect on [Ca2]1
and pH was observed. We observed tyrosine phosphorylation of
six distinct proteins in EC after EPO exposure, one of which
seems to be the transcription factor STAT-S. This phosphoprotein
underwent nuclear translocation after EPO. We conclude that
EPO signaling in EC is conducted via tyrosine phosphorylation
rather than by changes in [Ca2]1 or pH.
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Appendix
Abbreviations are: BCECF 2, 7-bis (carboyethyl)-5(6)-carboxyfluores-
cein; fura-2, 1(2(5-carboxyoxazol-2-yl)6-aminobenzofuran-5-oxyl-2-(2-
amino-5-methylphen-oxy)-ethane tetra-ethane acid.
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